Business
David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling
David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"\n \n \n David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling\n \n \nDavid Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling\n\nMajor Claims in J&J Lifescan Patent 7,250,105 Ruled \"Unpatentable\" by Three Judge USPTO Panel\n\n \n LOS ANGELES, CA--(Marketwired - Aug 11, 2014) - Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer of an exclusive worldwide sales, service and regulatory processes agent for its popular GenStrip™ glucose test strip, specifically designed to work with Johnson & Johnson's LifeScan Ultra family of glucose testing meters, announced today that on August 6, 2014, the United States Patent and Trademark Office, Patent Trial and Appeal Board has sustained, in a final ruling, the company's challenge to Johnson & Johnson Lifescan's Patent 7,250,105, specifically \"claims 1-3 ... for obviousness, ... by a preponderance of the evidence.\" These three claims are used by J&J Lifescan as the foundation of their patent infringement lawsuit against DECN and Pharma Tech. The USPTO Judge Panel has ruled these claims as \"unpatentable.\"\n The August 6, 2014 ruling marks the third ruling by a higher court on this same J&J Lifescan Patent. Previously in August 2013, in a preliminary ruling, the same USPTO three judge panel determined \"that Pharmatech has demonstrated that there is a reasonable likelihood of its proving the unpatentability of claims 1-3 of the '105 patent by a preponderance of the evidence.' In November 2013 the Federal Circuit Court, reversed an earlier ruling made in late March 2013 by a District Court judge in Northern California, and ruled that the J&J Lifescan patent rights (under patent 7,250,105) were subject to the doctrine of patent exhaustion. \n Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, \"The USPTO Patent Trial and Appeal Board's ruling along with the November 2013 Circuit Court's ruling, has put to rest significant parts of J&J Lifescan's lawsuit. We are delighted with this most recent ruling. We plan to continue our march forward without the distractions of frivolous lawsuits that have been used to create barrier...